Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): A randomised, open-label, phase 3, non-inferiority study

The Lancet

Volumn 385, Issue 9982, 2015, Pages 2057-2066

  Blonde, Lawrence ^a   Jendle, Johan ^b   Gross, Jorge ^c   Woo, Vincent ^d   Jiang, Honghua ^e   Fahrbach, Jessie L ^e   Milicevic, Zvonko ^f  

^a OCHSNER MEDICAL CENTER   (United States)

^b ÖREBRO UNIVERSITY   (Sweden)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d UNIVERSITY OF MANITOBA   (Canada)

^e ELI LILLY AND COMPANY   (United States)

^f Eli Lilly Research Laboratories   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

DULAGLUTIDE; HEMOGLOBIN A1C; INSULIN GLARGINE; INSULIN LISPRO; ANTIDIABETIC AGENT; GLARGINE; GLUCAGON LIKE PEPTIDE; GLYCOSYLATED HEMOGLOBIN; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; LONG ACTING INSULIN;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ANGINA PECTORIS; ARTHRALGIA; ARTICLE; BEDTIME DOSAGE; BRONCHITIS; CARDIOGENIC SHOCK; CARDIOVASCULAR DISEASE; CELLULITIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; HEADACHE; HEART VENTRICLE FIBRILLATION; HUMAN; HYPOGLYCEMIA; INFECTION; INFESTATION; INFLUENZA; INJECTION SITE REACTION; INSULIN TREATMENT; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEPTICEMIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VOMITING; ADOLESCENT; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; MIDDLE AGED; MULTICENTER STUDY; POSTPRANDIAL STATE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GLUCAGON-LIKE PEPTIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN FC FRAGMENTS; INSULIN LISPRO; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84930074468     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)60936-9     Document Type: Article

References (31)

1. DM Nathan, JB Buse, MB Davidson et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 32 2009 193 203
2. AJ Garber, MJ Abrahamson, JI Barzilay et al. AACE comprehensive diabetes management algorithm 2013 Endocr Pract 19 2013 327 336
3. LF Meneghini, D Orozco-Beltran, K Khunti et al. Weight beneficial treatments for type 2 diabetes J Clin Endocrinol Metab 96 2011 3337 3353
4. J Rosenstock, AJ Ahmann, G Colon, J Scism-Bacon, H Jiang, S Martin Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy Diabetes Care 31 2008 20 25
5. P Hollander, J Cooper, J Bregnhoj, CB Pedersen A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes Clin Ther 30 2008 1976 1987
6. P Raskin, T Gylvin, W Weng, L Chaykin Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes Diabetes Metab Res Rev 25 2009 542 548
7. J Rosenstock, B Ahren, FC Chow, V Fonseca, J Gross, R Ratner Once-weekly GLP-1 receptor agonist albiglutide vs titrated prandial lispro added on to titrated basal insulin glargine in type 2 diabetes (T2D) uncontrolled on glargine plus oral agents: similar glycemic control with weight loss and less hypoglycemia Diabetes 61 suppl 1 2012 A15
8. M Diamant, MA Nauck, R Shaqinian et al. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes Diabetes Care 37 2014 2763 2773
9. CH Wysham, T Blevins, R Arakaki et al. Efficacy and safety of dulaglutide added on to pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1) Diabetes Care 37 2014 2159 2167
10. GE Umpierrez, ST Povedano, FP Manghi, L Shurzinske, V Pechtner Efficacy and safety of dulaglutide monotherapy vs metformin in type 2 diabetes in a randomized controlled trial (AWARD-3) Diabetes Care 37 2014 2168 2176
11. Weinstock R, Umpierrez G, Guerci B, et al. Safety and Efficacy of Dulaglutide vs Sitagliptin after 104 Weeks in Type 2 Diabetes (AWARD-5). American Diabetes Association 73rd annual meeting; Chicago, IL, USA; June 23-21, 2013. 1004-P (abstr).
12. Z Skrivanek, BL Gaydos, JY Chien et al. Dose-finding results in an adaptive, seamless, randomised trial of once weekly dulaglutide combined with metformin in type 2 diabetes (AWARD-5) Diabetes Obes Metab 16 2014 748 756
13. M Nauck, RS Weinstock, GE Umpierrez, B Guerci, Z Skrivanek, Z Milicevic Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes (AWARD-5) Diabetes Care 37 2014 2149 2158
14. World Medical Association World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects JAMA 277 1997 925 926
15. MC Riddle, J Rosenstock, J Gerich The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients Diabetes Care 26 2003 3080 3086
16. RM Bergenstal, M Johnson, MA Powers et al. Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine Diabetes Care 31 2008 1305 1310
17. American Diabetes Association Standards of medical care in diabetes - 2010 Diabetes Care 33 suppl 1 2010 S11 S61
18. American Diabetes Association Workgroup on Hypoglycemia Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia Diabetes Care 28 2005 1245 1249
19. A Dmitrienko, AC Tamhane, BL Wiens General multistage gatekeeping procedures Biom J 50 2008 667 677
20. D Porte Jr, SE Kahn Beta-cell dysfunction and failure in type 2 diabetes: potential mechanisms Diabetes 50 suppl 1 2001 S160 S163
21. JJ Holst The physiology of glucagon-like peptide 1 Physiol Rev 87 2007 1409 1439
22. GE Umpierrez, T Blevins, J Rosenstock, C Cheng, JH Anderson, EJ Bastyr 3rd The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study Diabetes Obes Metab 13 2011 418 425
23. G Grunberger, A Chang, SG Garcia, FT Botros, R Bsharat, Z Milicevic Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study Diabet Med 29 2012 1260 1267
24. TJ Moretto, DR Milton, TD Ridge et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study Clin Ther 30 2008 1448 1460
25. DJ Drucker, JB Buse, K Taylor et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study Lancet 372 2008 1240 1250
26. A Garber, R Henry, R Ratner et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial Lancet 373 2009 473 481
27. KM Dungan, ST Povedano, T Forst et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial Lancet 384 2014 1349 1357
28. W Steinberg, JH DeVries, TA Wadden et al. Longitudinal monitoring of lipase and amylase in adults with type 2 diabetes and obesity: evidence from two phase 3 randomized clinical trials with the once-daily GLP-1 analog liraglutide Gastroenterology 142 suppl 1 2012 S850 S851
29. T Blevins, J Pullman, J Malloy et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes J Clin Endocrinol Metab 96 2011 1301 1310
30. JH DeVries, SC Bain, HW Rodbard et al. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets Diabetes Care 35 2012 1446 1454
31. J Rosenstock, VA Fonseca, JL Gross et al. Advancing basal insulin replacement in Type 2 diabetes inadequately controlled with a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin Lispro Diabetes Care 37 2014 2317 2325